The post‑pandemic era has accelerated demand across healthcare and life sciences, rewarding companies that address emerging patient and provider needs.
In 2024, Canadian health spending climbed 5.7% to approximately $268 billion, driven by aging demographics and new provider agreements. Across the US, healthcare is poised to deliver 45% of all job gains through 2032, reflecting sustained sector momentum.
It is also worth noting that biologics now account for roughly 40% of drug revenues, and GLP‑1 therapies are growing at nearly 30% annually, all in a landscape with inflated medical costs.
Meanwhile, 77% of health executives rank AI among their top three investment priorities, underscoring a sector‑wide pivot toward data‑driven care models.
Read on to meet the innovators selected by the Financial Times (FT) as the fastest growing healthcare companies in 2025, each expanding revenue and services in response to shifting market demands.
ABA Centers (Absolute Growth: 33,511%)
Founded in 2020, ABA Centers generated $196.9 million in revenue in 2023 — up from $0.59 million in 2020 — reflecting the rapid roll‑out of its home‑ and center‑based autism therapy programs. ABA Centers was named to Inc’s 2024 Best in Business list in the Health Services and “Robust and Powerful” categories.
Hydreight Technologies (Absolute Growth: 2,442%)
This Canadian mobile IV and wellness platform’s Q3 2024 revenue jumped to $6.12 million (up 54% compared to Q3 2023). This spring, the company broadened patient choice within its GLP‑1 portfolio — adding the daily injectable liraglutide alongside its existing offerings.
Seer (Absolute Growth: 2,439.8%)
Seer’s proteomics diagnostics platform uses proprietary nanoparticles to enrich low‑abundance proteins. In November 2024, Seer entered a co‑marketing and sales agreement with Thermo Fisher Scientific to expand the global reach of its Proteograph platform.
TScan Therapeutics (Absolute Growth: 1,840%)
Pioneering T‑cell receptor therapies, TScan targets solid tumors and autoimmune diseases. In March 2025, TScan extended its cash runway into Q1 2027 by raising $30 million via a registered direct offering and securing a $52.5 million term loan, fueling its upcoming TSC‑101 registration trials.
WELL Health Technologies (Absolute Growth: 1,444.7%)
This digital‑health integrator hit around $423 million in 2023 revenue through acquisitions in EMR, telehealth and cybersecurity across North America. In April 2025, WELL reported a record 2024 annual revenue of about $664 million — a 19% increase over the prior year.
Patriot Conceptions (Absolute Growth: 984%)
Specializing in gestational surrogacy, Patriot Conceptions supports intended parents worldwide. In March 2025, it introduced a digital platform to enhance transparency and streamline the surrogate‑matching process.
AscellaHealth (Absolute Growth: 753%)
As a pharmacy benefit manager (PBM) for specialty and rare therapies, AscellaHealth surpassed $710 million in 2023 revenue. In April 2025, it published its Q1 2025 Specialty & Rare Pipeline Digest, summarizing over 50 clinical updates on orphan drugs and novel therapies.
BeiGene (Absolute Growth: 696.1%)
Global oncology firm BeiGene moved from $308.9 million in 2020 revenue to $2.46 billion in 2023. BeiGene’s Tevimbra (tislelizumab‑jsgr) plus platinum‑based chemotherapy was recently FDA-approved as a first‑line treatment for adults with unresectable or metastatic, PD‑L1‑positive esophageal squamous cell carcinoma.
DocDelta (Absolute Growth: 587.3%)
AI‑driven workforce analytics provider DocDelta grew its top line from $0.57 million in 2020 to $3.89 million in 2023, reflecting health systems’ need for clinician‑recruitment insights. Their platform covers over 9 million healthcare contacts and 250,000 provider organizations nationwide.
DocGo (Absolute Growth: 563.5%)
DocGo delivers mobile health services for Medicaid and vulnerable populations. In February 2025, it acquired PTI Health, enabling mobile lab collection and in‑home phlebotomy to serve homebound patients.
Hims & Hers Health (Absolute Growth: 486%)
Evolving from a telehealth startup to a wellness platform, Hims & Hers topped $872 million in 2023 sales. The company recently acquired Trybe Labs to embed at‑home whole‑body biomarker testing, unlocking richer data for personalized treatment plans. This acquisition also powers its AI‑driven MedMatch platform.
LifeMD (Absolute Growth: 309%)
Growing from $37.3 million in 2020 to $152.55 million in 2023, LifeMD expanded its virtual care model by adding teletherapy, psychiatry and medication‑management services under new behavioral‑health leadership.
Premier Health of America (Absolute Growth: 335.8%)
Supplying nurses across Canada, Premier Health grew alongside rising provincial health budgets. In November 2024, it deployed AI in Quebec operations, achieving 89% precision in client‑data interpretation and improving efficiency by 25%.
RxAnte (Absolute Growth: 277.2%)
RxAnte’s analytical‑services business went from $17.7 million in 2020 revenue to $66.79 million in 2023. It was named one of New England’s fastest growing companies for its integration of analytics with pharmacy support.
TransparentRx (Absolute Growth: 224.6%)
A cost‑plus PBM, TransparentRx launched InSourceRx in 2024. This AI platform automates pharmacy‑benefit claims analysis and quickly flags specialty‑drug savings opportunities for brokers and self‑funded employers.
Twist Bioscience (Absolute Growth: 172%)
Synthetic‑DNA specialist Twist reached $245.1 million in 2023. Last month, it teamed with Curio Genomics to create a cost‑effective, end‑to‑end NGS workflow that lowers barriers for large‑scale agrigenomics projects.
ClarisHealth (Absolute Growth: 83.1%)
This payment‑integrity platform automates claims and denials under value‑based care. The company ranked #276 on the FT’s 2024 list of Americas’ Fastest Growing Companies, cementing its momentum in health tech.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN